Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel

22 August 2026 · By · Wire by Fusion42

Published

22 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at es.tradingview.com →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Capricor Therapeutics faces an imminent FDA decision on its drug Deramiocel for Duchenne muscular dystrophy, following previous rejection and an upcoming amendment submission with new efficacy data. Activist shareholder Kaos Capital is pushing for a board shakeup amid financial concerns, adding to investor uncertainty.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a sudden FDA decision shaping your biotech's FDA approval path and investor trust. The window to influence board direction and funding is open now.

◆ Coverage

1 source · 22 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-decisiondrug-approvalbiotechactivist-investorduchenne-muscular-dystrophy